Processing

Please wait...

Settings

Settings

Goto Application

1. WO2015084625 - IDENTIFICATION OF A NEW POLYPEPTIDE HORMONE FOR MAINTENANCE OF OPTIMAL BODY WEIGHT AND BLOOD GLUCOSE

Publication Number WO/2015/084625
Publication Date 11.06.2015
International Application No. PCT/US2014/067162
International Filing Date 24.11.2014
IPC
C07K 14/47 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
C07K 14/78 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin (CIG)
CPC
A61K 38/22
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
A61P 1/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
A61P 3/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
04Anorexiants; Antiobesity agents
A61P 3/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
A61P 3/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
10for hyperglycaemia, e.g. antidiabetics
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applicants
  • BAYLOR COLLEGE OF MEDICINE [US]/[US]
Inventors
  • CHOPRA, Atul
  • MOORE, David D.
Agents
  • SISTRUNK, Melissa L.
Priority Data
61/910,49802.12.2013US
62/010,55711.06.2014US
62/037,77915.08.2014US
62/073,50131.10.2014US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) IDENTIFICATION OF A NEW POLYPEPTIDE HORMONE FOR MAINTENANCE OF OPTIMAL BODY WEIGHT AND BLOOD GLUCOSE
(FR) IDENTIFICATION D'UNE NOUVELLE HORMONE POLYPEPTIDIQUE PERMETTANT LE MAINTIEN D'UN POIDS CORPOREL ET D'UNE GLYCÉMIE OPTIMAUX
Abstract
(EN)
Embodiments of the disclosure concern methods and compositions that relate to increasing or decreasing the weight (including, for example, by increasing or decreasing the adipose mass) in individuals in need thereof. Such methods and compositions, in particular embodiments, concern providing an effective amount of the hormone asprosin to increase adipose mass in an individual with insufficient adipose mass and providing an antibody or inhibitor of asprosin in an individual with obesity or diabetes, for example, to reduce adipose mass.
(FR)
L'invention concerne, selon divers modes de réalisation, des procédés et des compositions permettant une augmentation ou une réduction du poids (notamment, par exemple, grâce à une augmentation ou à une réduction de la masse adipeuse) chez des sujets en ayant besoin. Lesdits procédés et compositions, selon des modes de réalisation particuliers, impliquent d'utiliser une quantité efficace d'une hormone, l'asprosine, afin d'augmenter la masse adipeuse chez un sujet présentant une masse adipeuse insuffisante et d'administrer un anticorps dirigé contre l'asprosine ou un inhibiteur de l'asprosine chez un sujet souffrant d'obésité ou de diabète par exemple, pour réduire sa masse adipeuse.
Latest bibliographic data on file with the International Bureau